Special Issue

Heterogeneity in Intra-Cranial Tumors: Diagnostic, Prognostic, and Therapeutic Implications

Message from the Guest Editors

Recent advances have been made in diagnosing intracranial tumors, with a better definition of inter-tumoral heterogeneity. For instance, the WHO introduced a histo-molecular classification of gliomas in 2016, and new tumor entities, such as high-grade gliomas with piloid features, have been described. Additionally, there is also a high degree of intra-tumoral heterogeneity. Multiple tumor sampling and tumor resampling at progression have deciphered this heterogeneity at the spatial and temporal levels. From a functional viewpoint, the coexistence of areas characterized by different degrees of intrinsic connectivity has been demonstrated in gliomas. Moreover, single-cell analysis, notably applied to gliomas, has offered a better overview of inter- and intra-tumoral heterogeneity, identifying different transcriptomic signatures within the same tumor. This Special Issue aims to provide updated data regarding the inter- and intra-tumoral heterogeneity of intracranial neoplasms (gliomas, meningiomas, metastasis, etc.) and determine how this heterogeneity will influence therapeutic strategies and outcomes.

Guest Editors

Prof. Dr. Francois Ducray

Dr. Shawn L. Hervey-Jumper

Dr. Thiebaud Picart

Deadline for manuscript submissions

28 February 2026



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/213336

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

